4 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 5 Phase 1, 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Prostate Cancer (CRPC): new trials by email Literature Review of Prostate Cancer (CRPC) trials Research Report on Prostate Cancer (CRPC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide - Prostate Cancer (CRPC) | Phase 2 | Recruiting | TransThera Sciences (Nanjing), Inc. | 182 | 2026-09-18 | 2026-10-13 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) AB001 - Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | ARTBIO Inc. | 80 | 2025-11-03 | 2026-04-07 |
| Comparison of Peak Expiratory Flow Changes After Robot-Assisted Versus Open Radical Prostatectomy Surgical procedure: Robot-assisted laparoscopic radical prostatectomy - Prostate Cancer (CRPC), Peak Expiratory Flow | Not applicable | Active not recruiting | Ankara City Hospital Bilkent | 60 | 2025-11-01 | 2025-12-03 |
| Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity Prostate Cancer (CRPC) | Recruiting | Jonsson Comprehensive Cancer Center | 200 | 2025-07-17 | 2026-08-20 | |
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 Administering Lutetium-177-PSMA-617 (PLUVICTO) - Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis | Phase 2 | Recruiting | Ebrahim S Delpassand | 30 | 2025-05-23 | 2025-05-15 |
| Study on Human Bioequivalence of Triprerelin Acetate for Injection Triprorelin for injection, Diphereline - Prostate Cancer (CRPC) | Phase 1 | Recruiting | The Affiliated Hospital of Qingdao University | 120 | 2024-12-04 | 2024-11-12 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Tisotumab vedotin (HuMax-TF-ADC) - Ovary Cancer, Cervix Cancer | Phase 1 / Phase 2 | Completed | Seagen Inc. | 33 | 2015-11-30 | 2021-04-08 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Tisotumab Vedotin (HuMax-TF-ADC) - Ovary Cancer, Cervix Cancer | Phase 1 / Phase 2 | Completed | Seagen Inc. | 195 | 2013-11-30 | 2021-12-29 |
Prostatic Neoplasms (9) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Ovarian Neoplasms (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Disease (1) · Endometriosis (1) · Head and Neck Neoplasms (1) · Liver Cirrhosis (1) · Lung Neoplasms (1)
Genital Diseases (9) · Genital Diseases, Male (9) · Genital Neoplasms, Male (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
tisotumab vedotin (2) · Injections (1) · Pluvicto (1) · darolutamide (1) · enzalutamide (1)
Seagen Inc. (2) · ARTBIO Inc. (1) · Ankara City Hospital Bilkent (1) · Ebrahim S Delpassand (1) · Jonsson Comprehensive Cancer Center (1) · Martin Huellner (1) · The Affiliated Hospital of Qingdao University (1) · TransThera Sciences (Nanjing), Inc. (1)
United States (5) · Belgium (2) · China (2) · Denmark (2) · United Kingdom (2) · Hungary (1) · Sweden (1) · Switzerland (1) · Turkey (Türkiye) (1)
Johann de Bono, Professor (2) · Ebrahim S. Delpassand, M.D. Chairman & Medical Director, MD., Nuclear Medicine (1) · Luca Valle, MD (1)